

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 18 U.S.C. §208(b)(3)

Barbara Alexander, M.D.

Committee: Antiviral Drugs Advisory Committee

Meeting Date: April 24, 2007

I acknowledge that contingent upon public disclosure of the financial interest listed below, related to new drug application (NDA) 022-128, maraviroc 300 milligram tablets, sponsored by Pfizer, Inc., proposed for the treatment of antiretroviral-experienced patients with chemokine (c-c motif) receptor 5 (CCR5) - tropic human immunodeficiency virus (HIV), I am eligible to receive a waiver under 18 U.S.C. §208 (b)(3).

Type of Interest	Nature	Magnitude
Speaking	Sponsor	less than \$10,001

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

/S/
Signature of SGE

3/10/07
Date